Business Context and Reporting Period
Company: uniQure N.V. (formerly uniQure B.V.)
Reporting Period: Fiscal year ended December 31, 2013
Accounting Standard: International Financial Reporting Standards (IFRS)
Business Overview: uniQure is a gene therapy company focused on developing treatments for severe and chronic diseases. Its lead product, Glybera, received marketing approval in the European Union in October 2012 for the treatment of lipoprotein lipase deficiency (LPLD). The company operates primarily in the Netherlands and the United States, with manufacturing facilities in Amsterdam and a new facility under construction in Lexington, Massachusetts.
Key Financial Metrics (Year Ended Dec 31, 2013)
| Metric | 2013 (€ thousands) | 2012 (€ thousands) |
|---|---|---|
| Total Revenues | 2,943 | — |
| Cost of Goods Sold | (800) | — |
| Research & Development Expenses | (13,182) | (10,231) |
| Selling, General & Administrative Expenses | (11,628) | (4,564) |
| Net Loss | (26,820) | (14,716) |
| Cash and Cash Equivalents (Year End) | 23,810 | 263 |
| Total Debt | 7,864 | 1,498 |
| Accumulated Deficit | (144,041) | (117,234) |
Note: All figures in Euros unless otherwise noted. The company had no product sales revenue in 2013; revenues consisted of license amortization and collaboration reimbursements.
Material Changes vs. Prior Period
- Revenue Recognition: The company recorded €2.9 million in revenue in 2013, compared to zero in 2012. This was driven by €2.5 million in collaboration revenues (reimbursements from Chiesi) and €0.4 million in license revenues (amortization of upfront payments).
- Expense Growth: Selling, general, and administrative (SG&A) expenses surged 155% to €11.6 million, primarily due to increased headcount, share-based compensation, and costs associated with operating as a public company. R&D expenses increased 29% to €13.2 million as the company expanded clinical activities.
- Net Loss Expansion: Net loss widened to €26.8 million from €14.7 million. This was significantly impacted by a €3.5 million charge related to the revaluation and early conversion of embedded derivatives in convertible loans and venture debt.
- Liquidity Improvement: Cash and cash equivalents increased dramatically from €0.3 million in 2012 to €23.8 million in 2013. This was fueled by €17.0 million in upfront payments from Chiesi, €14.0 million in equity investment from Chiesi, and €12.0 million in convertible notes (later converted to equity).
- Debt Structure: Total debt increased to €7.9 million, primarily due to a new $10.0 million (€7.5 million) venture loan from Hercules Technology Growth Capital.
Guidance, Outlook, and Risks
Outlook and Guidance:
- Commercialization: The company expects to launch Glybera commercially in selected European countries in mid-2014 through its collaboration with Chiesi. It retains full commercial rights in the United States.
- U.S. Regulatory Path: The company plans to file an Investigational New Drug (IND) application with the FDA in the first half of 2014. It anticipates filing a Biologics License Application (BLA) in 2017, pending successful completion of additional clinical trials.
- Capital Needs: Management believes cash on hand (including IPO proceeds from February 2014) will fund operations for at least 12 months. However, the company expects to incur significant losses for several years and will likely need to raise additional capital.
Key Risks and Contingencies:
- Profitability: The company has an accumulated deficit of €144.0 million and expects to continue incurring significant losses. It has never achieved profitability.
- Regulatory Uncertainty: Glybera was approved in the EU under "exceptional circumstances," requiring ongoing post-approval studies and annual reassessments. FDA approval in the U.S. is not guaranteed and may require additional clinical data.
- Manufacturing: The company is building a new manufacturing facility in Lexington, MA. Delays in construction or regulatory approval of this facility could hinder U.S. commercialization.
- Internal Controls: The company identified three material weaknesses in its internal control over financial reporting (lack of accounting resources, lack of comprehensive policies, and lack of segregation of duties) during the 2013 audit.
- Collaboration Dependence: Commercial success in Europe depends heavily on Chiesi's ability to market and sell Glybera.
Investor Verification Checklist
- Commercial Launch Timeline: Verify the actual launch date of Glybera in the EU and initial sales performance against the "mid-2014" expectation.
- U.S. Regulatory Milestones: Monitor the filing of the IND application and the design/approval of the post-approval clinical trial required by the FDA.
- Manufacturing Progress: Track the completion and regulatory validation of the Lexington, Massachusetts manufacturing facility.
- Cash Burn Rate: Assess the rate of cash consumption relative to the €23.8 million cash balance and the timing of any future capital raises.
- Internal Control Remediation: Review subsequent filings for updates on the remediation of the three identified material weaknesses in internal controls.
- Chiesi Collaboration: Monitor Chiesi's progress in securing pricing and reimbursement approvals in key EU markets.